With $270M, Beam spinoff Orbital Therapeutics builds RNA medicines as it hunts for partners, more delivery tech

Kyle LaHucik

Senior Reporter

Orbital Therapeutics, the RNA medicines upstart formed by base editing biotech Beam Therapeutics, is out with a $270 million Series A to fuel work across …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $270M, Beam spinoff Orbital Therapeutics builds RNA medicines as it hunts for partners, more delivery tech

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

With $270M, Beam spin­off Or­bital Ther­a­peu­tics builds RNA med­i­cines as it hunts for part­ners, more de­liv­ery tech

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

With $270M, Beam spinoff Orbital Therapeutics builds RNA medicines as it hunts for partners, more delivery tech